ESMO 2014: Roche's cobimetinib and Perjeta; Specialised Therapeutics Australia's anamorelin
Swiss drug major Roche (ROG: SIX) presented positive results from a Phase III study of cobimetinib plus Zelboraf (vemurafenib) in people with advanced melanoma against the use of Zelboraf alone.
Those with previously untreated BRAF V600 mutation-positive, advanced melanoma who received the MEK inhibitor cobimetinib and Zelboraf had significantly higher rates of progression-free survival than those treated with Zelboraf alone.
The findings were presented today at the European Society for Medical Oncology (ESMO) Congress, in Madrid, Spain, and Roche has submitted an EU marketing authorization application for the combination therapy in the treatment of BRAF V600 mutation-positive advanced melanoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze